Observations on the metabolism of the psychotomimetic indolealkylamines: implications for future clinical studies.
Biological psychiatry November 15, 1990 DOI: 10.1016/0006-3223(90)90566-k via PubMed
Summary
AI-generated from the abstractThe psychotomimetic indolealkylamines N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and 5-hydroxy-N,N-dimethyltryptamine have been found in human body fluids, but their link to psychotic illness is still debated. Studies in rats show these compounds are rapidly metabolized and excreted by the kidneys. This rapid clearance may explain inconsistencies in past clinical research and should inform the design of future studies.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Citations | 29 |
| Key finding | The rapid metabolism and renal excretion of psychotomimetic indolealkylamines in rats suggests that past clinical studies may have been confounded by these pharmacokinetics, and future studies should account for this. |
Abstract
Although the psychotomimetic indolealkylamines N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and 5-hydroxy-N,N-dimethyltryptamine have been unequivocally identified in human body fluids, evidence relating their concentration to the presence of psychotic illness in humans remains controversial. A series of studies on the metabolism of the compounds in the rat have highlighted the rapidity and with which these are metabolized and renally excreted. The implications of our observation for the interpretation of past clinical studies and the design of future ones is discussed.